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Study Importance
What is already known?
► Mitochondrial pyruvate carriers (MPCs) 
are essential for pyruvate to be trans-
ported into the mitochondria and 
 utilized as substrate by the pyruvate 
dehydrogenase complex for energy 
production.
What does this study add?
► This study is novel because it demon-
strates that MPCs are not required for 
the adipogenesis of 3T3-L1 cells, sug-
gesting that other substrates may com-
pensate for energy production during in 
vitro adipogenesis.
► This study is also novel because it 
shows that MPCs are regulated by 
diet-induced obesity in brown adipose 
tissue.
Objective: The objectives of this study were to assess the role of mito-
chondrial pyruvate carriers (MPCs) in adipocyte development in vitro and 
determine whether MPCs are regulated in vivo by high-fat feeding in male 
and female C57BL/6J mice.
Methods: This study utilized small interfering RNA-mediated knockdown 
to assess the requirement of MPC1 for adipogenesis in the 3T3-L1 model 
system. Treatment with UK-5099, a potent pharmacological MPC inhibi-
tor, was also used to assess the loss of MPC activity. Western blot analy-
sis was performed on adipose tissue samples from mice on a low-fat diet 
or a high-fat diet (HFD) for 12 weeks.
Results: The loss of MPC expression via small interfering RNA-mediated 
knockdown or pharmacological inhibition did not affect adipogenesis 
of 3T3-L1 cells. In vivo studies indicated that expression of MPCs was 
significantly decreased in brown adipose tissue of male mice, but not 
female, on an HFD.
Conclusions: Although MPCs are essential for pyruvate transport, MPCs 
are not required for adipogenesis in vitro, suggesting that other substrates 
can be used for energy production when the MPC complex is not func-
tional. Also, a significant decrease in MPC1 and 2 expression occurred in 
brown fat, but not white fat, of male mice fed an HFD.
Obesity (2020) 28, 293-302.
Introduction
The mitochondrial pyruvate carriers (MPCs) are transmembrane pro-
teins, found on the inner mitochondrial membrane, that transport pyru-
vate from the cytosol into the mitochondrial matrix where pyruvate is 
oxidized to acetyl coenzyme A (acetyl CoA) and carbon dioxide via the 
pyruvate dehydrogenase complex. Acetyl CoA is utilized in the citric 
acid cycle to form reduced nicotinamide adenine dinucleotide (NADH) 
for oxidative phosphorylation to create a proton gradient for the produc-
tion of ATP via the ATP synthase complex. There are two MPC proteins 
in mammals (MPC1 and MPC2), but there are three that have been 
identified in Saccharomyces cerevisiae (MPC1, MPC2, and MPC3) (1). 
In mammals, MPC1 and MPC2 form a heterodimer to actively transport 
pyruvate into the mitochondria (2). Because MPC1 and MPC2 act in a 
codependent manner, the loss or deletion of one of these proteins results 
in the loss of the other MPC because of destabilization (2-4). The study 
of MPC1 mutants has confirmed that dimerization of MPC1 and MPC2 
in the inner mitochondrial membrane is essential for pyruvate uptake 
into the mitochondria (3).
MPC1 expression may also play a role in cancer metabolism as inhibi-
tion of MPC complex formation, via UK-5099, hinders pyruvate’s entry 
into the mitochondria and is associated with increased glycolysis (5). 
Increased glycolysis is a distinct metabolic feature of cancer cells, along 
with mitochondrial reprogramming and decreased lipid metabolism (6). 
The MPC inhibitor 2-Cyano-3-(1-phenyl-1H-inodl-3-yl)-2-propenic 
acid (UK-5099) binds to MPCs, which deactivates the MPC complex 
and inhibits pyruvate oxidation (7). Thiazolidinediones inhibit MPCs in 
several cell types, and in skeletal muscle, inhibition of MPCs is asso-
ciated with increased glucose uptake and increased insulin sensitivity. 
Using the CRISPR/Cas9 (clustered regularly interspaced short palin-
dromic repeats/CRISPR-associated protein 9) system, a heterozygous 
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MPC1 knockdown model was generated, and these mice had reduced 
lipid accumulation, increased lipolysis, enhanced fatty acid oxidation, 
and decreased energy expenditure (8). During adipogenesis, mitochon-
drial density is increased by 20- to 30-fold along with increases in 
mitochondrial gene expression and oxidative capacity to meet increas-
ing energy requirements (9-13). Insufficient or reduced mitochondrial 
density in tissues with a high energy demand (such as the brain, heart, 
and muscles) and endocrine organs (such as adipose tissue) is associated 
with disease states (14). Although MPCs have been studied in several 
cell and tissue types, the role of these proteins in adipocyte development 
and their regulation in conditions of obesity are not known.
In our novel studies, we examined the requirement of MPC1 during 
adipocyte development using two independent approaches. Both phar-
macological inhibition of MPCs as well as small interfering RNA (siR-
NA)-mediated knockdown of MPC1 demonstrated that the expression 
and/or activity of MPC1 was not required for adipogenesis in 3T3-L1 
cells. To our knowledge, this is the first siRNA-mediated MPC1 knock-
down reported in 3T3-L1 cells. However, siRNA-mediated knockdown 
of MPC1 and MPC2 in 832/13 β-cells resulted in impaired insulin secre-
tion in response to glucose and reductions in glucose-stimulated oxygen 
consumption (15). We also examined the modulation of MPC expres-
sion in both brown (BAT) and white adipose tissue (WAT) depots of 
male and female mice in a rodent model of diet-induced obesity (DIO). 
Expression levels of MPC1 and MPC2 were substantially decreased in 
the BAT of male mice following high-fat feeding, but not in female mice 
under the same conditions. In conclusion, our results indicate that loss 
of MPC1 does not have any effect on adipogenesis of 3T3-L1 preadipo-
cytes, MPC1 and MPC2 are highly expressed in BAT, and MPC1 and 
MPC2 are modulated by high-fat feeding in BAT of male mice.
Methods
Animals and diets
Four-week-old male and female C57BL/6J mice were purchased from 
Jackson Laboratories (Stock #000664; Bar Harbor, Maine). Animals 
were housed in a temperature-controlled (22°C ± 2°C) and humidity- 
controlled (45%-55%) room under a 12-hour light/dark cycle. At 6 weeks 
of age, mice were placed on respective diets. Mice were allowed  ad 
libitum  access to food and water. For 12 weeks, mice had access to 
either a low-fat diet (LFD) containing 20% of kilocalories from protein, 
70% of kilocalories from carbohydrate, and 10% of kilocalories from 
fat (D12450J; Research Diets, Inc., New Brunswick, New Jersey) or a 
high-fat diet (HFD) containing 20% of kilocalories from protein, 20% 
of kilocalories from carbohydrate, and 60% of kilocalories from  fat 
(D12492; Research Diets). Body weights were obtained biweekly. Mice 
were fasted for 4 hours prior to euthanasia. All animal studies were per-
formed with approval from the Pennington Biomedical Research Center 
Institutional Animal Care and Use Committee.
Animal body composition and glucose tolerance 
measurements
Nonfasting body composition was measured by nuclear magnetic res-
onance (NMR) (Bruker Minispec, Bruker BioSpin Corp., Billerica, 
Massachusetts) at 6 weeks of age (before beginning LFD or HFD in-
tervention) and at 19 weeks of age (after 12 weeks of LFD or HFD 
feeding). Adiposity was calculated as total fat mass ÷ total body 
weight × 100. Following a 4-hour fast, an intraperitoneal glucose toler-
ance test (GTT) was performed on each animal at 17 weeks of age (10 
weeks on diet). A baseline blood glucose measurement was obtained 
via tail nick (0 minutes), and animals were then injected with 2.5 g/
kg of glucose. Blood glucose measurements were obtained via a drop 
of blood collected from the tail vein at 20, 40, 60, and 120 minutes post 
injection. Blood glucose measurements were performed using a Breeze 
2 glucometer (Bayer, Parsippany, New Jersey).
Cell culture
Murine 3T3-L1 preadipocytes were grown in DMEM (Sigma-Aldrich, St. 
Louis, Missouri) with 10% bovine calf serum. Two days after confluence, 
the preadipocytes were induced to differentiate using a standard protocol 
and induction cocktail composed of MDI cocktail (3-isobutyl-1-methylx-
anthine  [IBMX], dexamethasone, insulin) and 10% characterized fetal 
bovine serum (FBS)  in DMEM. HyClone bovine calf serum and FBS 
were purchased from Thermo Scientific (Waltham, Massachusetts) or GE 
Healthcare Life Sciences (Marlborough, Massachusetts). The medium 
was changed every 48 to 72 hours during growth and differentiation.
Pharmacological inhibitor (UK-5099) treatments
3T3-L1 preadipocytes were trypsinized and seeded into six-well plates at 
a density of 5.8 × 105 cells/cm2 in antibiotic-free 10% bovine calf/DMEM 
when approximately 70% confluent in 10-cm plates. 3T3-L1 preadipo-
cytes were treated with 10µM UK-5099 (Sigma-Aldrich; PZ0160) added 
to the medium upon seeding. Preadipocytes were induced to differen-
tiate as previously described. Cells were fed with antibiotic-free media 
and treated with UK-5099 every 48 hours. Seven days after the induction 
of differentiation, the cell monolayers were harvested for protein in im-
munoprecipitation (IP) buffer containing 10mM Tris (pH 7.4), 150mM 
NaCl, 1mM EGTA, 1mM EDTA, 1% Triton X-100, 0.5% IGEPAL CA-
630 (octylphenoxypolyethoxyethanol), protease inhibitors (1mM phenyl-
methylsulfonyl fluoride  [PMSF], 1μM pepstatin, 50 trypsin inhibitory 
milliunits of aprotinin, 10μM leupeptin, and 1mM 1,10-phenanthroline), 
and phosphatase inhibitors (0.2mM sodium vanadate and 100µM sodium 
fluoride) and were harvested for RNA in buffer provided in the RNeasy 
Mini Kit (Qiagen, Hilden, Germany) to assess knockdown efficiency. 
Three biological and technical replicates were analyzed for each dose. 
All reagents used to make the IP buffer were from Sigma-Aldrich.
Cytotoxicity and cell viability assays
The ToxiLight BioAssay Kit (Lonza, Cologne, Germany) was utilized 
according to the manufacturer’s protocol. ToxiLight 100% lysis reagent 
(Lonza) was utilized as a positive control. Cell viability was assessed by 
counting trypan blue-stained cells using a hemacytometer.
Whole-cell extract preparation
Cell monolayers were rinsed once with phosphate-buffered saline 
(PBS) and then scraped into non-denaturing IP buffer. The whole-cell 
extracts were stored at −80°C before being thawed and passed through 
a 20-gauge needle five times. The whole-cell extract was clarified via 
centrifugation at 13,000g for 10 minutes at 4°C.
siRNA-mediated knockdown
3T3-L1 preadipocytes were trypsinized and replated in six-well plates 
at a density of 5.8 × 105 cells/cm2 in antibiotic-free 10% bovine calf/
DMEM when approximately 70% confluent in 10-cm plates. Using the 
protocol from Dharmacon, preadipocytes were transfected with 33nM 
siRNA (Dharmacon, Lafayette, Colorado; nontargeting siRNA Cat#: 
D-001810-10-50, siRNA targeting MPC1 Cat#: L-040908-01-0005) and 
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the DharmaFECT Duo transfection reagent (Dharmacon; Cat#: T-2010-
03) in Opti-MEM reduced serum medium (Thermo Fisher, Waltham, 
Massachusetts; Cat#: 31985088). Nontargeting siRNA was used as a neg-
ative control. Cells were treated with the siRNA cocktail during initial 
plating and grown to confluence. Two days after confluence, cells were 
induced to differentiate with the MDI induction cocktail, as previously de-
scribed, and transfected again with the siRNA cocktail. After 48 hours, 
the cells were treated with one-quarter normal dose of insulin and trans-
fected once again with the siRNA cocktail. Cells were fed every 48 hours 
with antibiotic-free media throughout the entire knockdown process. 
Seven days after the induction of differentiation, the cell monolayers were 
harvested for protein in IP buffer and for RNA in buffer provided in the 
RNeasy Mini Kit to assess knockdown efficiency. Three biological and 
technical replicates were analyzed for each dose.
Respirometry
Mitochondrial function was assessed by respirometry of intact cells using a 
Seahorse XFe24 Analyzer (Agilent Technologies, Santa Clara, California). 
Mature 3T3-L1 adipocytes were seeded at 1.0 × 105 cells per well in an 
XF24 specialized cell culture microplate that was coated with 0.1% gela-
tin for 48 hours prior to seeding. Prior to measuring oxygen consumption, 
cells were incubated in XF base media, pH 7.4 (Agilent Technologies) 
supplemented with 25mM glucose and 2mM L-glutamine at 37°C without 
CO2 for 1 hour. After basal oxygen consumption was measured for three 
cycles, 1mM sodium pyruvate ± 10µM UK-5099 was injected into each 
well. After three additional measurement cycles, 1µM oligomycin, 600nM 
carbonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP), and 5µM 
rotenone/antimycin A were serially injected, and oxygen consumption was 
measured for three, six, and three cycles, respectively. After the assay was 
complete, cells were harvested in radioimmunoprecipitation assay (RIPA) 
buffer, and protein concentration was quantified using the bicinchoninic 
acid (BCA) assay kit (Sigma-Aldrich; Cat#: BCA1). Oxygen consumption 
rate was normalized to micrograms of protein.
Gel electrophoresis and immunoblotting
Protein content of cell extracts was quantified via BCA assay. Samples 
were separated on 7.5%, 12%, or 15% sodium dodecyl sulfate (SDS) poly-
acrylamide gels (acrylamide; National Diagnostics, Atlanta, Georgia; 
Cat#: EC-890) and transferred to nitrocellulose membranes (BioRad, 
Hercules, California; Cat#: 162-0115) in 25mM Tris, 192mM glycine, and 
20% methanol. After the transfer, membrane strips were blocked in 4% 
nonfat milk for 1 hour at room temperature and washed with Tris-buffered 
saline  - Tween 20 (TBS-T) before incubating with primary antibodies 
overnight at 4°C. Strips were washed with TBS-T and then incubated with 
either anti-mouse or anti-rabbit horseradish peroxidase-conjugated sec-
ondary antibodies (Jackson ImmunoResearch, West Grove, Pennsylvania) 
for 1 hour. Strips were washed with TBS-T and visualized with enhanced 
chemiluminescence (Pierce/Thermo Scientific, Waltham, Massachusetts).
Antibodies
Anti-STAT  (signal transducer and activator of transcription)  5A (L-20; 
sc-1081; rabbit polyclonal), anti-adipsin (M-120; sc-50419; rabbit poly-
clonal), anti-STAT3 (C-20; sc-482; rabbit polyclonal), and anti-ERK (ex-
tracellular signal-regulated kinase)  1/2 (C-16; sc-93; rabbit polyclonal) 
antibodies were purchased from Santa Cruz Biotechnology (Dallas, 
Texas). Anti-adiponectin (PA1-054; rabbit polyclonal) antibody was pur-
chased from Thermo Scientific. Anti-MPC1 (14462S; rabbit monoclonal) 
and anti-MPC2 (D4I7G; rabbit monoclonal) antibodies were purchased 
from Cell Signaling Technology (Danvers, Massachusetts).
RNA analysis 
Total RNA from tissue samples was extracted according to TRIzol manu-
facturer instructions (Ambion, Carlsbad, California; Cat#15596018). RNA 
from tissue or adipocyte monolayers was purified using the RNeasy Mini Kit. 
Ten microliters of purified RNA was used for reverse transcription to gen-
erate complementary DNA (cDNA) according to the Applied Biosystems 
protocol (Applied Biosystems, Foster City, California; Cat#: 4368813). 
Complementary DNA was quantified using the real-time quantitative poly-
merase chain reaction (qPCR) method in a total volume of 10 µL (2 µL DNA 
and 8 µL reaction master mix) using an Applied Biosystems 7900HT system 
with SDS 2.4 software. qPCR was performed using Takara SYBR Premix 
(Takara Bio USA Inc., Madison, Wisconsin) and primers from Integrated 
DNA Technologies (Skokie, Illinois). Thermal cycling conditions were as 
follows: 2 minutes at 50°C, 10 minutes at 95°C, and 40 cycles of 15 seconds at 
95°C; the dissociation stage was 15 seconds at 95°C, 15 seconds at 60°C, and 
15 seconds at 95°C. Cyclophilin A (Ppia; also known as  peptidylprolyl 
isomerase A)  and non-POU domain containing octamer binding protein 
(Nono) were used as reference genes. The following mouse genes were ex-
amined by reverse transcription (RT)-qPCR: oxoglutarate dehydrogenase 
(Ogdh), succinate dehydrogenase complex iron sulfur subunit B (Sdhb), 
Mpc1, Mpc2, CCAAT/enhancer  binding protein, alpha (Cebpa), peroxi-
some proliferator-activated receptor gamma (Pparg), adiponectin (Adpn), 
citrate synthase (Cs), fatty acid binding protein 4 (Ap2), fatty acid synthase 
(Fas; also known as TNF receptor superfamily member 6),  and adipsin 
(Cfd). Primer sequences are shown in Table 1.
Lipid accumulation measurement
Seven days after the induction of differentiation, cells were fixed and 
stained with Oil Red O (Sigma-Aldrich) as described previously (16).
Statistical analysis
Statistical analyses were performed using GraphPad Prism software (ver-
sion 8; La Jolla, California). Differences between groups were calculated 
using t tests and two-way ANOVA. Area under the curve (AUC) calcula-
tions and standard linear regression analyses were performed to determine 
correlations between MPC protein expression and adiposity or GTT AUC. 
Results from studies of cultured adipocytes are shown as mean ± SEM. 
Results were considered statistically significant when P < 0.05.
Results
Loss of MPC1 has no effect on in vitro 
adipogenesis
Prior to determining the potential requirement for MPC1 expression for 
adipocyte differentiation, we examined the protein expression of MPC1 
and MPC2 over a 7-day adipogenesis time course in 3T3-L1 cells. As 
shown in Figure 1, both MPC1 and MPC2 protein expressions were highly 
induced during differentiation. The increased expression was apparent 
4 days after the induction of adipogenesis (Figure 1A-1B). To assess the 
requirement of MPCs on adipogenesis, we used a potent pharmacolog-
ical inhibitor of MPCs, UK-5099, which acts by binding to MPCs and 
modifying a thiol group to prevent the formation of the MPC1 and MPC2 
heterodimer, thus reducing pyruvate transport into the mitochondrial ma-
trix (17,18). Preadipocytes were induced to differentiate in the presence 
of UK-5099 at various doses. As shown in Figure 2, a range of inhibitor 
doses did not inhibit adipocyte differentiation as judged by lipid accu-
mulation with Oil Red O staining (Figure 2A) or adipocyte marker gene 
expression (Figure 2B). Three adipogenic markers (Adpn, Ap2, Fas) were 
examined to demonstrate adipocyte development.
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To examine the efficacy of UK-5099, respirometry experiments were 
performed on 3T3-L1 cells to measure oxygen consumption in the pres-
ence of pyruvate with or without the addition of the inhibitor. There 
were no differences in oxygen consumption observed during baseline 
readings after the addition of pyruvate ± UK-5099 or oligomycin. After 
the addition of FCCP, the maximal oxygen consumption rates in 3T3-
L1 cells treated with the inhibitor were significantly reduced compared 
with the control (1.167 vs. 3.411 pmol/min/µg protein) (Figure 2C-2D). 
Oxygen consumption rates were reduced by UK-5099 in the presence 
of the mitochondrial uncoupler, FCCP, likely because of a reduction of 
pyruvate substrate entry into the mitochondria. Cell viability and cyto-
toxicity assays show that UK-5099-treated 3T3-L1 cells had no changes 
in cytotoxicity (Figure 2E) or cell viability (Figure 2F) in comparison 
with dimethyl sulfoxide (DMSO), which indicates that UK-5099 has no 
toxic effects on the cells.
An independent approach using siRNA-mediated knockdown of MPC1 
was also performed to examine the role of MPCs on adipogenesis in 
3T3-L1 cells. Despite substantial loss of MPC1 protein expression 
(Figure 3A-3B), there were no observed changes in adiponectin protein 
expression or lipid accumulation (Figure 3A-3C). Though Mpc1 gene 
expression was significantly reduced, mRNA expression of Mpc2 and 
adipogenic markers, such as Adpn, Ap2, and Pparg, was not affected 
(Figure 3D). Although Cebpa gene expression increased in the absence 
of MPC1, this increase did not affect adipogenesis. These data confirm 
that loss of MPC1 expression does not have any significant effects on 
adipogenesis of 3T3-L1 cells.
MPCs are regulated in adipose tissue of mice 
during high-fat feeding
To further study MPCs, we examined MPC1 and MPC2 protein ex-
pression in several adipose tissue depots and compared it with other 
tissues in mice. As shown in Figure 4, MPC1 and MPC2 were highly 
expressed in BAT, heart, liver, and kidneys in C57BL/6J mice. When 
directly compared, it was apparent that there were differences in protein 
TABLE 1 qPCR primer sequences
Gene Primer 1, 5′-3′ Primer 2, 5′-3′
Cyclophilin A (Ppia) CCACTGTCGCTTTTCGCCGC TGCAAACAGCTCGAAGGAGACGC
Non-POU domain containing octamer binding protein (Nono) CATCATCAGCATCACCACCA TCTTCAGGTCAATAGTCAAGCC
Oxoglutarate dehydrogenase (Ogdh) ATGGGAAAGACCAAAGCTGA CCATGCAGCAGGATAGACAT
Succinate dehydrogenase complex, subunit B, iron sulfur (Sdhb) GGAGGGCAAGCAACAGTATC GCACACAGGATGCACTCGTA
Mitochondrial pyruvate carrier 1 (Mpc1 ) CAAGGACTTCCGGGACTATC CATCCGCCCACTGATAATCTC
Mitochondrial pyruvate carrier 1 (Mpc2 ) CCGACTCATGGATAAAGTGGAG CTAGTCCAGCACACACCAAT
Adiponectin (Adpn) AAAAGGGCTCAGGATGCTACTG TGGGCAGGATTAAGAGGAACA
Citrate synthase (Cs) AGAACTCATCCTGCCTCGT CCTGCTCCTTAGGTATCAGATTG
Fatty acid binding protein 4 (Ap2 ) CCCTCCTGTGCTGCAGCCTTT GTGGCAAAGCCCACTCCCACTT
Fatty acid synthase (Fas) GGCATCATTGGGCACTCCTT ACCACCAGCTGCCATGGATC
Adipsin (Cfd ) CGAGGCCGGATTCTGGG GAGTCGTCATCCGTCACTCC
CCAAT/enhancer binding protein, alpha (Cebpa) ACAAGAACAGCAACGAGTACC TCATTGTCACTGGTCAACTCC
Peroxisome proliferator-activated receptor gamma (Pparg) CGAGTGGTCTTCCATCACGG TCACAAGAAATTACCATGGTTGAC
Figure 1 MPC1 and MPC2 expression are induced during adipogenesis in 3T3-L1 cells. 3T3-L1 adipocytes 
were induced to differentiate using the 3-isobutyl-methylxanthine, dexamethasone, insulin (MDI) cocktail, and 
whole-cell extracts were harvested at the indicated time points to assess MPC1 protein expression over a time 
course of adipocyte differentiation. (A) Whole-cell extracts (75 µg of protein per lane) were subjected to Western 
blot analysis. Adiponectin was utilized as a positive control for adipogenesis. (B) Densitometry quantification 
of MPC1 and MPC2 band intensities at the indicated time points. MPC1 and MPC2 band intensities were 
normalized to ERK 1/2 (n = 3 pooled 10-cm plates per time point). Experiments were repeated three times on 
independent batches of cells.
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expression of MPC1 and MPC2 in some tissues. MPC1 had a much 
higher protein expression than MPC2 in the skeletal muscle, in both 
the extensor digitorum longus and the gastrocnemius, and in the brain 
(Figure 4). Also, the levels of MPC1 and MPC2 expression were low in 
all of the WAT depots (Figure 4).
To determine whether MPC expression was regulated by DIO, mice 
were placed on either LFD or HFD for 12 weeks. BAT, inguinal WAT 
(iWAT), and gonadal/epididymal WAT (gWAT) were harvested and 
analyzed in both male and female mice on LFD or HFD. In both male 
and female mice, Mpc1 mRNA expression was significantly decreased 
in the BAT, iWAT, and gWAT during high-fat feeding of male and 
female mice, while Mpc2 mRNA expression was decreased in the 
gWAT of males and the BAT and gWAT of females during high-fat 
feeding (Figure 5). We also observed an expected decrease in Fas gene 
expression during high-fat feeding (19). Protein expression of both 
MPC1 and MPC2 in BAT was significantly reduced in male mice on 
an HFD (Figure 6A-6B). This significant decline in MPC1 and MPC2 
levels was not observed in the female mice fed an HFD (Figure 6C-
6D). In iWAT, MPC1 protein expression was extremely low, near the 
detection limit, and no changes in protein levels were observed as a 
result of HFD feeding (data not shown). These data indicate that MPC 
gene expression is downregulated in a depot and sex-specific manner 
by high-fat feeding.
Because female C57BL/6 mice are typically less susceptible to 
metabolic dysfunction during HFD-induced obesity than their male 
counterparts (20-22), we examined the relationships between MPC1 
or MPC2 protein expression and adiposity or glucose tolerance. 
Protein expression of MPC1 and MPC2 for males significantly cor-
related with adiposity and GTT AUC for male, but not female, mice 
(Figure 7). For the male mice, the linear fits of MPC1 or MPC2 versus 
Figure 2 UK-5099, a pharmacological inhibitor of MPC1, does not inhibit adipogenesis of 3T3-L1 cells. (A,B) 3T3-L1 preadipocytes were induced to differentiate either 
untreated or treated with DMSO vehicle or indicated dose of UK-5099 at the time of induction and every 2 days during differentiation. (A) Seven days post induction, cells 
were fixed and stained with Oil Red O. Photographs are from the same experiment, and wells (n = 3 wells per treatment) were treated at the same time. (B) Seven days 
post induction, RNA was isolated, purified, and subjected to RT-qPCR to measure gene expression of Mpc1, adipogenic markers (adiponectin [Adpn], fatty acid binding 
protein 4 [Ap2], and fatty acid synthase [Fas]), and the mitochondrial marker citrate synthase (Cs) (n = 3 wells per treatment). Target gene expression was normalized to the 
reference gene, Nono, and data are plotted as fold change over the DMSO control. (C,D) Respirometry experiments were performed to demonstrate the efficacy of the MPC1 
inhibitor in mature 3T3-L1 adipocytes. After introducing 1mM pyruvate ± 10µM UK-5099, the oxygen consumption rate (OCR) was measured using a Seahorse XF analyzer 
for three cycles prior to performing the mitochondrial stress test using 1µM oligomycin (Oligo), 600nM FCCP, and 5µM rotenone (Rot)/antimycin A (AA). (C) Full respiration 
profile showing the mean OCR normalized by the protein content ± SEM for each well (n = 10 wells per treatment). (D) Maximal respiration after the addition of 600nM FCCP 
(n = 10 wells per treatment). Data shown are mean OCR of cells treated with pyruvate (P) or pyruvate and UK-5099 (P + I). Panels C and D were analyzed by unpaired t test. 
****P < 0.0001 vs. pyruvate control. Experiments were repeated at least twice on independent batches of cells. (E,F) Seven days post induction, UK-5099-treated 3T3-L1 
cells were either (E) subjected to cytotoxicity assay via ToxiLight BioAssay Kit or (F) stained with trypan blue and counted to assess cell viability at indicated doses (n = 3 wells 
per treatment for a single batch of cells).
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adiposity or GTT AUC had an R2 value of greater than 0.5, and the 
slopes were significantly nonzero (P < 0.01), whereas female mice R2 
values were less than 0.4, and none of the slopes was significantly 
nonzero. These data show that decreased levels of MPC proteins in 
male mice were associated with increased adiposity and decreased 
glucose tolerance.
Figure 3 Knockdown of Mpc1 gene expression with siRNA does not inhibit adipogenesis of 3T3-L1 cells. 3T3-L1 preadipocytes 
were transfected with nontargeting (NT) siRNA or MPC1 siRNA upon plating and every 48 hours following induction of 
differentiation with MDI cocktail until end point assessments. Protein and gene expression assessments as well as Oil Red 
O staining were conducted on the cells at 7 days post MDI. (A) Whole-cell extracts were isolated and 50 µg of protein per 
lane was analyzed by Western blot analysis (n = 3 replicate wells per treatment). Adiponectin was utilized as a differentiated 
adipocyte marker. (B) MPC1 band intensities were quantified by densitometry and normalized to ERK 1/2 for each treatment. 
(C) Cells were fixed and stained with Oil Red O to examine lipid accumulation. (D) RNA was isolated, purified, and subjected 
to RT-qPCR to show gene expression of Mpc1, Mpc2, adipogenic markers (adiponectin [Adpn], fatty acid binding protein 4 
[Ap2], CCAAT/enhancer binding protein, alpha [Cebpa], and peroxisome proliferator-activated receptor gamma [Pparg]), and 
the mitochondrial marker (citrate synthase [Cs], oxoglutarate dehydrogenase [Ogdh], and succinate dehydrogenase complex, 
subunit B, iron sulfur [Sdhb]). Data were analyzed by two-way ANOVA. *P < 0.05, **P < 0.01, and ***P < 0.001 vs. NT control 
(n = 3 wells per treatment).
Figure 4 MPC1 and MPC2 proteins are highly expressed in brown adipose tissue, liver, and heart. Select 
tissues were harvested from a 27-week-old C57BL/6J mouse to assess the tissue distribution of MPC1 and 
MPC2 proteins. (A) Tissue samples were homogenized, and 100 µg of total protein per lane was analyzed 
by Western blotting. (B) MPC1 and MPC2 band intensities were quantified by densitometry and normalized 
to respective ERK 1/2 intensities for each tissue depot. BAT, brown adipose tissue; EDL, extensor digitorum 
longus; gastroc, gastrocnemius; gWAT, gonadal white adipose tissue (WAT); iWAT, inguinal WAT; mWAT, 
mesenteric WAT; rpWAT, retroperitoneal WAT. 
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Figure 5 Steady-state mRNA expression of Mpc1 is substantially decreased in adipose tissue after high-fat feeding 
in male and female C57BL/6J mice. Six-week-old C57BL/6J mice were fed either an HFD or LFD (low fat, LF) for 12 
weeks ad libitum before euthanizing and collecting tissue. Brown adipose tissue (BAT), inguinal white adipose tissue 
(iWAT), and gonadal white adipose tissue (gWAT) samples were homogenized, and RNA was isolated and purified 
from each tissue depot for (A) male and (B) female mice. Each sample was subjected to RT-qPCR to show gene 
expression of Mpc1, Mpc2, adipogenic markers (Adpn, Ap2, and Fas), adipokine (Adipsin), and the mitochondrial 
marker (Cs). Data were analyzed by unpaired t tests. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 vs. LFD 
(n = 6 per condition). Each sample was run in duplicate. Target gene expression was normalized to the reference 
gene, Ppia, and data are plotted as fold change over the LF control.
Figure 6 MPC1 and MPC2 expression is significantly decreased in the BAT of male mice, but not female, following 
high-fat feeding. Six-week-old male and female C57BL/6J mice were fed either a high-fat diet (HFD) or low-fat 
diet (LFD) for 12 weeks ad libitum before euthanizing and collecting BAT. Tissue samples were homogenized, and 
30 µg of total protein per lane was subjected to Western blot analysis (n = 6 per condition) for (A) males and (C) 
females. MPC1 and MPC2 band intensities were quantified by densitometry and normalized to respective STAT3 
intensities for each sample; (B) males and (D) females. Data were analyzed by two-way ANOVA. **P < 0.01 vs. LFD.
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Discussion
Our novel data demonstrate the dispensability of MPC1 during adi-
pogenesis in vitro as well as show the expression and modulation of 
MPCs in BAT in vivo during DIO. The observed increase in protein 
expressions of both MPC1 and MPC2 during adipocyte differentiation 
of 3T3-L1 cells (Figure 1) has not been previously reported in 3T3-L1 
cells, but MPC1 and MPC2 expression  was shown to increase upon 
differentiation of leucine-rich repeat-containing G-protein coupled re-
ceptor 5 (LGR5)+ intestinal stem cells (23). The increase in MPC1 and 
MPC2 expression in adipocytes is likely due to increased mitochondrial 
density and gene expression that occurs to generate energy needed to 
accommodate the enhanced metabolic requirements during adipogene-
sis (9,12,13). Because of enhanced protein expression of MPCs during 
differentiation, we hypothesized that MPCs were necessary for the dif-
ferentiation of 3T3-L1 cells.
Contrary to our premise, two independent approaches using both phar-
macological inhibition with UK-5099 (Figure 2) and siRNA-mediated 
knockdown (Figure 3) of MPCs did not affect adipocyte development. 
Even at doses as low as 50nM, UK-5099 has been able to inhibit for-
mation of the MPC1 and MPC2 heterodimer, thus inhibiting pyruvate 
transport via this complex (4,17). In BAT progenitor cells, the addition 
of UK-5099 inhibited 13C-glucose incorporation into acetyl CoA (17), 
suggesting that the pyruvate produced from glycolysis of 13C-glucose 
was not utilized for acetyl CoA production because of impaired pyru-
vate uptake by the MPC heterodimer via UK-5099 inhibition. Liver-
specific loss of MPC2 in C57BL/6J mice resulted in compromised, but 
not eliminated, pyruvate metabolism and suggested that mechanisms 
such as pyruvate-alanine cycling were activated to compensate for the 
loss of the MPC complex functionality (24). A robust decline (~80%) 
in MPC1 expression via siRNA knockdown also had no effect on adi-
pocyte development (Figure 3). Our data further support the current lit-
erature. Our observations suggest that although pyruvate is the primary 
substrate for energy production in the mitochondria, other substrates, 
such as alanine, glutamine (2,24,25), or branched chain amino acids 
(26), might bypass the MPC1/2 complex and enter into the mitochon-
drial matrix to compensate for the lack of pyruvate transport under 
Figure 7 Decreased MPC1 and MPC2 protein expression in BAT during DIO correlates with increased adiposity 
and decreased metabolic health in male, but not female, mice. (A,B) MPC protein expression from the immunoblot 
quantification in Figure 6 was correlated with percent fat mass (adiposity) for male and female mice on LFD and 
HFD. Protein extracts were collected and adiposity measured at 19 weeks of age (12 weeks on diet). (C,D) MPC 
protein expression values for male and female mice were also plotted against area under the curve (AUC) of glucose 
tolerance tests (GTT) performed on LFD- and HFD-fed mice at 17 weeks of age (10 weeks on diet) for male and 
female mice. Linear regression analyses were performed and are shown. R2 values indicate goodness of the linear 
fit for each data set, and whether the slope is significantly differently from zero is denoted by P value or marked “ns” 
(not significant).
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conditions in which MPC1 or MPC2 is not present or functional. A 
clear limitation of our adipogenesis studies is that they are solely in 
vitro observations. Although our findings show that the loss of MPC 
expression in vitro has no effect on adipocyte development, other 
in vivo studies have found that C57BL/6 mice with an adipocyte-spe-
cific loss of MPC1 had increased fatty acid oxidation, increased levels 
of triglycerides in circulation, deficiencies in storage of triglycerides, 
and mitochondrial damage. It also has been observed that heterozy-
gous MPC1 knockdown mice had decreased body weight, activity, and 
fat accumulation and low body shell temperatures during cold expo-
sure (8,27).
An analysis of several mouse tissue samples revealed that MPCs were 
highly expressed in BAT, heart, lung, and skeletal muscle (Figure 4). 
This is an expected finding because these are all mitochondria-rich 
tissues. However, it has not been reported that MPC1 and MPC2 are 
more highly enriched in BAT than other mitochondria-rich tissues 
(Figure 4). Because MPCs are highly enriched in BAT depots, but not 
in WAT depots, we assessed whether MPCs were regulated in adipose 
tissue depots during DIO. Although MPC1 was downregulated in BAT 
and WAT during high-fat feeding at the mRNA level (Figure 5), MPC1 
protein expression was barely detectable and not obviously changed in 
the WAT of either male or female mice during high-fat feeding (data 
not shown). The differences in gene and protein expression could be 
due to a variety of factors, including translational rates, protein deg-
radation rates, or a combination of both (28). However, it is a novel 
finding that MPC gene and protein expression is downregulated in 
BAT of male mice, but not female, during DIO (Figures 5,6). It was 
reported that reductions in diet-induced thermogenesis contributed 
to weight gain after consumption of high-fat meals (29). In addition, 
glucose oxidation rates were significantly decreased in individuals 
after consuming high-fat meals (29). This literature suggests that the 
decreased MPC expression correlated with decreased diet-induced 
thermogenesis that occurs with prolonged high-fat feeding. Also, 
the sex-specific regulation of MPCs (Figure 6) is likely attributed to 
sex-specific metabolic responses to high-fat feeding in C57BL/6J mice 
(21). Unlike male mice, previous studies have shown that female mice 
were more metabolically healthy, had reduced inflammation, and were 
more insulin sensitive despite having obesity while on an HFD (20-22). 
Accordingly, in our study the female mice on an HFD had 27% higher 
adiposity than the male HFD-fed mice but improved glucose metabo-
lism during an intraperitoneal GTT. Data in Figure 7 demonstrate that 
decreased MPC protein levels correlate with increased adiposity and 
glucose intolerance in male, but not female, mice. We speculate that 
the variations in expression of MPC1 and MPC2 between male and 
female mice are due to differences in metabolic health and that MPCs 
are specifically regulated in BAT, but not WAT, depots in conditions of 
metabolic dysfunction.
In summary, our findings demonstrate that (1) the expression of MPCs 
is induced during adipocyte development but not required for adipo-
genesis; (2) a loss of MPC expression or activity during adipogenesis 
likely promotes the activation of alternative mechanisms to compen-
sate for the loss of pyruvate transport; and (3) MPC expression is 
highly enriched in BAT but decreased as a result of high-fat feeding 
or DIO. Future studies will be needed to determine which substrates 
can be utilized to compensate for the loss or dysfunction of MPCs. In 
addition, it is necessary to determine whether adipogenesis in BAT is 
dependent on MPCs. Also, future studies will be necessary to deter-
mine whether the observed in vitro effects on adipogenesis are similar 
to in vivo models. O
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